Contact
Score Calculators
Publications
Advancing knowledge in chronic liver disease through evidence-based research.
AbstractsPublication policy

Showing 3 of 3 papers

Personalised human albumin in patients with cirrhosis and ascites: Design and rationale for the ALB-TRIAL – A randomised clinical biomarker validation trial

Torp N, Israelsen M, Coenraad M, Papp M, Shawcross D, Korenjak M, Angeli P, Laleman W, Juanola A, Gines P, Trebicka J, Krag A; MICROB-PREDICT Consortium.

BMJ Open 2024, 14(2): e079309

DOI: 10.1136/bmjopen-2023-079309

The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

Reiberger T, Berzigotti A, Trebicka J, Ertle J, Gashaw I, Swallow R, Tomisser A.

Trials 2023, 24(1): 293

DOI: 10.1186/s13063-023-07291-3

Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: Study protocol for a randomized controlled trial

Madsen BS, Trebicka J, Thiele M, Israelsen M, Arumugan M, Havelund T, Krag A.

Trials 2018, 19(1): 143

DOI: 10.1186/s13063-018-2523-9

Registered office

European Foundation for the Study of
Chronic Liver Failure
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain

Legal

Contact us

T +34 93 227 14 00
E efclif@efclif.com

© European Foundation for the Study of Chronic Liver Failure 2024